LOGIN  |  REGISTER
Assertio

ICU Medical to Present at the Raymond James 46th Annual Institutional Investors Conference

February 13, 2025 | Last Trade: US$129.90 1.97 -1.49

SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 46th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-5, 2025. ICU Medical’s presentation will be on Monday, March 3, 2025 at 5:40 a.m. PT (8:40 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, March 3, 2025.

The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay.

About ICU Medical

ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

CONTACT:
ICU Medical
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page